Janux Therapeutics Inc
JANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$889.76M
Close$
$-3.71
127.3% downside
Current Fair Value
127.3% downsideOvervalued by 127.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $889.76 Million |
|---|---|
| Enterprise Value | $897.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 2.57 |
| Outstanding Shares | 62,665,717 |
Return
| Return on Equity | -16.84% |
|---|---|
| Return on Assets | -15.42% |
| Return on Invested Capital | -19.66% |
Valuation & Multiples
| P/E Ratio | -7.99 |
|---|---|
| PEG | -220.11 |
| Price to Sales | - |
| Price to Book Ratio | 0.91 |
| Enterprise Value to Revenue | 41.51 |
| Enterprise Value to EBIT | -4.71 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$4.36 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$17.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9174▼ 136.37% |
|---|---|
| Total Calls | 449,880▲ 11.19% |
| Total Puts | 412,700▼ 55.28% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 96.16%▼ 4.13% |
|---|---|
| Total Invested | $827.82M▼ 3.74% |
| Investors Holding | 199▲ 11.00% |
ESG Score
No data
About Janux Therapeutics Inc
16 employees